Identification of a novel small-molecule modulator targeting SNX10 to inhibit osteoclastic bone resorption

Clicks: 12
ID: 326304
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #42 of 122 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Current antiresorptive therapies reduce bone loss by eliminating osteoclasts or inhibiting their formation. However, these approaches could disrupt osteoclast-osteoblast communication and cause serious complications with long-term usage. There is a need for developing new therapies that selectively inhibit resorptive function, while preserving osteoclast-mediated coupling effects to osteoblasts. Sorting nexin 10 (SNX10), an autosomal recessive osteopetrosis (ARO)-associated gene, plays a role mainly in osteoclast bone resorptive function. However, its potential as a target for developing therapeutic agents for bone disorders remains unexplored. In this study, we employed a multi-step approach combining artificial intelligence (AI)-driven virtual screening with high-throughput screening methods and functional assays to identify small molecules targeting SNX10 that inhibit bone resorption without impairing osteoclast formation. Our lead compound AW-006 emerged as the top candidate across all validation methods, selectively inhibiting osteoclast resorptive function while maintaining normal osteoclastogenesis in vitro. Mechanistic analyses indicated that AW-006 interacts with SNX10 and reduces its thermal stability, while molecular docking predicted binding within the PI(3)P-binding pocket and associated conformational changes affecting residues involved in PI(3)P binding and structural integrity. We discovered that SNX10 interacts with the key vesicular trafficking regulator Rab7 in living cells, and AW-006 abnormally enhances this interaction, dysregulating normal podosome belt formation in osteoclasts. Furthermore, the compound's anti-resorptive efficacy was validated in ovariectomized mice, demonstrating its therapeutic potential in estrogen deficiency-induced bone loss. Our study identifies AW-006 as a novel anti-resorptive candidate and highlights SNX10 as a promising therapeutic target for bone disorders.
Reference Key
openalex_W7204037704 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yihe Li, Qihang Wu, Shengnan Qin, Ruth Seeber, Benjamin H. Mullin, Ariela Samantha, Hui Li, Ke Liu, Jie Fan, Kai Chen, Scott G. Wilson, Alice Vrielink, Haiming Jin, Jiake Xu
Journal journal of bone and mineral research : the official journal of the american society for bone and mineral research
Year 2026
DOI
10.1093/jbmr/zjag126
URL
https://academic.oup.com/jbmr/advance-article-pdf/doi/10.1093/jbmr/zjag126/70765659/zjag126.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.